{"id":"NCT01830621","sponsor":"NCIC Clinical Trials Group","briefTitle":"BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma","officialTitle":"A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-10","primaryCompletion":"2016-05-07","completion":"2016-05-16","firstPosted":"2013-04-12","resultsPosted":"2019-03-11","lastUpdate":"2023-08-28"},"enrollment":282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Carcinoma"],"interventions":[{"type":"DRUG","name":"BBI608","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Best Supportive Care","otherNames":[]}],"arms":[{"label":"BBI608","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to find out whether it is better to receive a new drug, BBI608, or better to receive no further treatment for colon or rectal cancer. To do this, half of the patients in this study will get BBI608 and the other half will receive a placebo (a substance that is designed not to do anything).","primaryOutcome":{"measure":"Overall Survival","timeFrame":"36 month","effectByArm":[{"arm":"BBI608","deltaMin":4.44,"sd":null},{"arm":"Placebo","deltaMin":4.76,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.337"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":25,"exclusionCount":12},"locations":{"siteCount":63,"countries":["Australia","Canada","Japan"]},"refs":{"pmids":["29397354"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":136},"commonTop":["Fatigue","Diarrhea","Nausea","Anorexia","Abdominal pain"]}}